Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis

Journal of Autoimmune Diseases

Volumn 6, Issue 1, 2009, Pages

  Parker, Jennifer C ^a   Burlingame, Rufus W ^b   Bunn, Christopher C ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AMINO ACID TRANSFER RNA LIGASE ANTIBODY; ANTIBODY KU; ANTIBODY RO 52; ANTIBODY RO 60; AUTOANTIBODY; KU ANTIGEN; SMALL NUCLEAR RIBONUCLEOPROTEIN; SMALL NUCLEAR RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; COUNTER IMMUNOELECTROPHORESIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MYOSITIS; RADIOIMMUNOPRECIPITATION; SEROPREVALENCE; SYSTEMIC SCLEROSIS;

EID: 62149100398     PISSN: None     EISSN: 17402557     Source Type: Journal    
DOI: 10.1186/1740-2557-6-2     Document Type: Article

References (22)

1. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. E Ben-Chetrit EKL Chan KF Sullivan EM Tan, J Exp Med 1988 167 1560 1571 3367095 10.1084/jem.167.5.1560
2. Anti-Ro-52 reactivity is an independent and additional serum marker in connective tissue disease. I Peene L Meheus S De Keyser R Humbel EM Veys F De Keyser, Ann Rheum Dis 2002 61 929 933 12228166 10.1136/ard.61.10.929
3. Recombinant 52 kDa Ro (SSA) ELISA detects autoantibodies in Sjogrens syndrome that go undetected by conventional serologic assays. DP McCauliffe L Wang M Satoh WH Reeves D Small, J Rheumatol 1997 24 860 866 9150073
4. Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjogrens syndrome. E Ben-Chetrit RI Fox EM Tan, Arthritis Rheum 1990 33 349 355 10.1002/art. 1780330307 2107806
5. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. I Peene L Meheus EM Veys F De Keyser, Ann Rheum Dis 2002 61 1090 1094 12429541 10.1136/ard.61.12.1090
6. Neonatal lupus syndromes. JP Buyon A Rupel RM Clancy, Lupus 2004 13 705 712 10.1191/0961203304lu2008oa 15485109
7. Anti-Ro-52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. SA Rutjes WTM Vree Egberts P Jongen F Van den Hoogen GJM Pruijn WJ Van Venrooij, Clin Exp Immunol 1997 109 32 40 9218821 10.1046/j.1365-2249.1997.4081308.x
8. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. MB Frank V McCubbin E Trieu Y Wu DA Isenberg IN Targoff, J Autoimmunity 1999 12 137 142 10.1006/jaut.1998.0265
9. Autoantibody profiles in the sera of European patients with myositis. R Brouwer GJD Hengstman W Vree Egberts H Ehrfeld B Bozic A Ghirardello G Grondal M Hietarinta D Isenberg JR Kalden I Lundberg H Moutsopoulos P Roux-Lombard A Vencovsky A Wikman H Seelig BGM van Engelen WJ van Venrooij, Ann Rheum Dis 2001 60 116 123 11156543 10.1136/ard.60.2.116
10. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. C Sordet J Goetz J Sibilia, Joint Bone Spine 2006 73 646 654 10.1016/j.jbspin.2006.04.005 17110150
11. Scleroderma - clinical and pathological advances. CP Denton CM Black, Best Pract Res Clin Rheumatol 2004 18 271 290 15158741
12. Autoantibodies in systemic sclerosis. VD Steen, Semin Arthritis Rheum 2005 35 35 42 10.1016/j.semarthrit.2005.03.005 16084222
13. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980 23 581 90 10.1002/art.1780230510 7378088
14. Identification of antibodies to acidic antigens by counterimmunoelectrophoresis. RM Bernstein CC Bunn GRV Hughes, Ann Rheum Dis 1982 41 554 555 6982030 10.1136/ard.41.5.554
15. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. CC Bunn CP Denton X Shi-Wen C Knight CM Black, Br J Rheumatol 1998 37 15 20 10.1093/rheumatology/37.1.15 9487245
16. Epitope mapping with synthetic peptides of 52-kD SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera. V Ricchiuti JP Briand O Meyer DA Isenberg G Pruijn S Muller, Clin Exp Immunol 1994 95 397 407 7511075
17. Anti-Ro (SS-A) 52 kDa and 60 kDa specificities in undifferentiated connective tissue disease. N Belfiore S Rossi F Bobbio-Pallavicini O Epis R Caporali C Montecucco, Joint Bone Spine 2000 67 183 187 10875315
18. Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-a autoantibodies in Japanese patients with systemic sclerosis. M Fujimoto M Shimozuma N Yazawa M Kubo H Ihn S Sato T Tamaki K Kikuchi K Tamaki, Ann Rheum Dis 1997 56 667 670 9462169 10.1136/ard.56.11.667
19. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. M Koenig MJ Fritzler IN Targoff Y Troyanov Senecal J-C, Arthritis Research Therapy 2007 9 R78 17688695 10.1186/ar2276
20. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. C Marguerie CC Bunn J Copier RM Bernstein JM Gilroy CM Black AK So MJ Walport, Medicine 1992 71 327 336 10.1097/00005792- 199211000-00001 1435228
21. Anti-fibrillarin antibodies in systemic sclerosis. VJ Tormey CC Bunn CP Denton CM Black, Rheumatology 2001 40 1157 1162 10.1093/rheumatology/40.10.1157 11600746
22. Clinical significance of anti-Ku autoantibodies - a serological marker of overlap syndrome? T Mimori, Intern Med 2002 41 1096 1098 10.2169/ internalmedicine.41.1096 12521194